Market Intelligence, Clinical Progress, and High-Purity Reagents for Lymphangiogenesis and Angiogenesis Modulation.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for VEGFD (FIGF) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Human) | Human FIGF (VEGFD) Recombinant Protein, HEK293 Active homodimer, >95% purity, Sequence Verified, Endotoxin <1EU/µg |
View FIGF Products |
| Antigen (Ortholog) | Cynomolgus Monkey FIGF Protein Sequence Verified; Critical for NHP pharmacokinetic bridging studies |
View FIGF Products |
| Antigen (Ortholog) | Mouse FIGF Protein For syngeneic tumor model validation; Endotoxin Controlled |
View FIGF Products |
| Benchmark Ab | Anti-VEGFD Neutralizing Antibody (Reference Biosimilar Sequence) Recombinant human IgG control for blocking assays |
View FIGF Products |
| Gene Delivery | FIGF ORF Lentivirus (Premade Particles) For stable overexpression in lymphatic endothelial reporter lines |
View FIGF Products |
| Validator | FIGF siRNA Set (3 Unique Targeting Sequences) For specificity confirmation in functional knockdown assays |
View FIGF Products |
| Related Target | VEGFC (Vascular Endothelial Growth Factor C) 55% homology; Essential for specificity counter-screening |
View VEGFC Products |
| Related Target | FLT4 (VEGFR3 / Fms-like Tyrosine Kinase 4) Primary receptor for FIGF; Required for binding competition assays |
View FLT4 Products |
| Related Target | KDR (VEGFR2 / Kinase Insert Domain Receptor) Secondary receptor; Cross-reactivity liability assessment |
View KDR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| VEGFC Homology Discrimination | High-resolution Mass Spec Verified Identity; Human FIGF with <0.1% detectable VEGFC contamination |
| VEGFR2/VEGFR3 Selectivity Profiling | Native HEK293 Expression ensuring correct cysteine-knot disulfide formation for physiologic receptor binding |
| Cross-species Cyno/Mouse Evaluation | Ortholog Panel Available: Human, Cynomolgus, Mouse; Sequence Verified with 95%+ identity |
| False Positive Blockade | Validated siRNA Set included for target engagement confirmation; eliminates off-target antibody artifacts |
| Functional Activity Correlation | Theoretical MW confirmed by SDS-PAGE (reducing/non-reducing); Purity >95% for consistent EC50 in bioassays |
Live VEGFD R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VEGFD-targeted therapeutics is intensifying as understanding of lymphatic-mediated metastasis deepens. While first-generation VEGF inhibitors (anti-VEGFA) face resistance via compensatory VEGFD upregulation, next-generation modalities are specifically targeting VEGFD to block lymphangiogenesis in solid tumors. Major players are pivoting from broad-spectrum VEGF traps to highly specific monoclonal antibodies and bispecific constructs that spare VEGFA-dependent homeostatic angiogenesis. As first-in-class molecules enter Phase I/II trials for lymphedema and oncology indications, the critical differentiator lies in achieving exquisite selectivity over VEGFC and managing VEGFR2 versus VEGFR3 signaling bias.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing mAb | Emerging Biotech, Regeneron (VEGF Trap legacy) | Solid Tumors (Lymphatic Metastasis), Lymphedema | VEGFC Cross-reactivity ELISA (Need highly pure FIGF antigen) |
| Receptor Trap (VEGFR3-Fc) | Academic/Spin-out | Inflammatory Disease | Receptor Binding Competition (Need native conformation FIGF) |
| Bispecific (Anti-VEGFA/VEGFD) | Oncology-focused Biotechs | Ovarian, Breast Cancer | Dual Binding Assay (Need both FIGF and VEGFA proteins) |
| Small Molecule (RTK Inhibitor) | Global Pharma | Advanced Cancers | Selectivity Panel (Need FIGF/VEGFC/VEGFA protein family) |
Molecular Differentiation & Assay Strategy
Developing best-in-class VEGFD therapeutics requires overcoming significant molecular challenges:
- Affinity & Selectivity: VEGF family members are highly homologous. Antibodies must exhibit exquisite specificity for VEGFD over VEGFA and VEGFC to minimize systemic cardiovascular side effects. Assay recommendation: SPR or high-throughput ELISA cross-reactivity screening using a full VEGF family protein panel.
- Protein Processing: VEGFD is secreted as a full-length precursor and cleaved to a mature form (containing the central VHD domain) with much higher affinity for VEGFR2/3. Assay recommendation: Receptor neutralization assays to evaluate blockade of mature VEGFD binding to VEGFR3/VEGFR2.
- Safety: Immunogenicity must be minimized for systemic or intravitreal administration. TarMart provides HEK293-expressed, native glycosylated VEGFD protein with endotoxin <1EU/µg to ensure accurate cellular assays.
Related Targets for Cross-Selling
To support comprehensive pathway studies and bispecific antibody development, consider the following related targets:
- VEGFC: Key counter-screen control; also a compensatory pathway when VEGFD is inhibited.
- FLT4 (VEGFR3): Primary receptor for VEGFD; required for binding competition assays.
- KDR (VEGFR2): Secondary receptor; cross-reactivity liability assessment.
- NRP2 (Neuropilin-2): Co-receptor for VEGFD, modulating binding efficiency to VEGFR3; expressed in neurons and lymphatic endothelium.